Fundraising FoxAbfero Pharmaceuticals
Lexington, US · Founded 2016 · Delaware corporation
Find your way into Abfero Pharmaceuticals
Sign up to see every warm intro you have to Abfero Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abfero Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Abfero Pharmaceuticals is a clinical-stage pharmaceutical company developing oral iron chelators that target iron as a therapeutic pathway for diseases of iron overload. Its lead brain-penetrant small molecule, SP-420, is aimed at conditions such as transfusional systemic iron overload and age-related macular degeneration.
Founders & leadership
TX
Thomas X. NeenanExecutive
SB
Steven BurkeExecutive
Board
MP
Michael PeningtonBoard director
Reported raises · per SEC filings
Form D private placements$1.8M disclosed across 3 rounds · 2019–2021
▶$500KraisedMar 2021 · 2 investors · BiotechnologyRule 506(b)
▶$500KraisedMar 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael PeningtonDirector
- Thomas X NeenanExecutive Officer, Director
- Steven BurkeExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $500K
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$680KraisedJun 2020 · 4 investors · BiotechnologyRule 506(b)
▶$680KraisedJun 2020 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven BurkeExecutive Officer, Director
- Thomas X. NeenanExecutive Officer, Director
- Michael PeningtonDirector
- Offering amount
- $2M
- Amount sold
- $680K
- Minimum investment
- $30K
- Proceeds to insiders
- $270K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$600KraisedApr 2019 · 6 investors · BiotechnologyRule 506(b)
▶$600KraisedApr 2019 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas X. NeenanExecutive Officer, Director
- Michael PeningtonDirector
- Steven BurkeExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $600K
- Minimum investment
- $50K
- Proceeds to insiders
- $100K
- First sale
- Feb 2019
- Incorporated
- Corporation, Massachusetts, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Abfero Pharmaceuticals do?
- Abfero Pharmaceuticals is a clinical-stage pharmaceutical company developing oral iron chelators that target iron as a therapeutic pathway for diseases of iron overload. Its lead brain-penetrant small molecule, SP-420, is aimed at conditions such as transfusional systemic iron overload and age-related macular degeneration.
- How much funding has Abfero Pharmaceuticals raised?
- Abfero Pharmaceuticals has disclosed $1.8M raised across 3 rounds.
- Where is Abfero Pharmaceuticals headquartered?
- Abfero Pharmaceuticals is headquartered in Lexington, US.